The Association between Vaginal Dysbiosis and Reproductive Outcomes in Sub-Fertile Women Undergoing IVF-Treatment: A Systematic PRISMA Review and Meta-Analysis
- PMID: 33806442
- PMCID: PMC8001118
- DOI: 10.3390/pathogens10030295
The Association between Vaginal Dysbiosis and Reproductive Outcomes in Sub-Fertile Women Undergoing IVF-Treatment: A Systematic PRISMA Review and Meta-Analysis
Abstract
Recent advances in molecular microbiology have enabled refined studies of the genital tract microbiota. This constitutes the basis of the present updated systematic review and meta-analysis which investigate vaginal dysbiosis (VD) as defined by either microscopy (e.g., Nugent score for bacterial vaginosis) or molecular methods (qPCR and Next Generation Sequencing) to evaluate the impact of VD on the reproductive outcomes in women undergoing IVF-treatment. A total of 17 studies were included, comprising 3543 patients and with a VD prevalence of 18% (95%CI 17-19). Across all methods, VD is a significant risk factor for early pregnancy loss in IVF (Relative risk (RR) = 1.71 95%CI 1.29-2.27). Moreover, a predefined sub-analysis of studies using molecular methods for VD diagnosis showed a significant reduction in the clinical pregnancy rate when compared to normal vaginal microbiota patients (RR = 0.55 95%CI 0.32-0.93). However, regardless of diagnostic methodology, VD did not significantly influence live birth rate (LBR). In conclusion, molecular tools have provided a more detailed insight into the vaginal microbiota, which may be the reason for the increased adverse effect estimates in IVF patients with molecularly defined VD. However, the quality of evidence was very low across all outcomes according to GRADE and thus, more studies are warranted to understand the impact of VD in IVF.
Keywords: IVF; bacterial vaginosis; clinical pregnancy rate; next generation sequencing; qPCR; vaginal microbiota.
Conflict of interest statement
Outside this study, TH has received honoraria for lectures from Ferring, IBSA, Besins and Merck. PH received unrestricted research grants from MSD, Merck, and Ferring as well as honoraria for lectures from MSD, Merck, Gedeon-Richter, Theramex, and IBSA. JSJ has received speaker’s fee from Hologic, BD, SpeeDx, and Cepheid and serves scientific advisory board of Roche Molecular Systems, Abbott Molecular, and Cepheid. PH, TH and JSJ received an unrestricted research grant from Osel inc. which produces LACTIN-V, a live biotherapeutic product with
References
-
- Haahr T., Ersbøll A.S., Karlsen M.A., Svare J., Sneider K., Hee L., Weile L.K., Ziobrowska-Bech A., Østergaard C., Jensen J.S., et al. Treatment of bacterial vaginosis in pregnancy in order to reduce the risk of spontaneous preterm delivery—A clinical recommendation. Acta Obstet. Gynecol. Scand. 2016;95:850–860. doi: 10.1111/aogs.12933. - DOI - PubMed
-
- Moreno I., Codoner F.M., Vilella F., Valbuena D., Martinez-Blanch J.F., Jimenez-Almazan J., Alonso R., Alama P., Remohi J., Pellicer A., et al. Evidence that the endometrial microbiota has an effect on implantation success or failure. Am. J. Obstet. Gynecol. 2016;215:684–703. doi: 10.1016/j.ajog.2016.09.075. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
